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Abstract
Background: Hepatocellular carcinoma (HCC) recurs in 10-60% of 
patients after liver transplantation and carries very dismal prognosis. Optimal 
management of this condition has yet to be defined.
Patients and Methods: All adult patients with HCC within the UCSF 
(University of California, San Francisco) criteria who underwent liver 
transplantation at Queen Mary Hospital during the period from July 1995 
to September 2013 were reviewed. Two hundred and fifty-two patients were 
included in the analysis. They were divided into three groups for comparison: 
with intrahepatic recurrence (IR), with multiple or extrahepatic recurrence (MR), 
with no recurrence (NR).
Results: HCC recurrence occurred in 35 (13.9%) patients, 3 with IR and 
32 with MR. Patients in the IR and MR groups had a younger age (51 vs. 51 
vs. 56 years; p=0.007), a higher pretransplant serum α-fetoprotein level (27 
vs. 97.5 vs. 18 ng/mL; p=0.005), more tumor nodules (4 vs. 2 vs. 1; p=0.003) 
and a higher incidence of lymphovascular permeation (33% vs. 59% vs. 27%; 
p=0.001) than patients in the NR group. More patients in the IR and MR groups 
had tumors beyond the UCSF criteria on histopathology (67% vs. 56% vs. 17%) 
when compared with the NR group. Treatments for IR included hepatectomy, 
radiofrequency ablation and transarterial chemoembolization. One patient with 
IR remained alive 3 years after last treatment. Overall survival in the IR group 
was longer than that in the MR group (59 vs. 30.4 months; p<0.001). Time 
from transplant to recurrence was similar between the two groups (23.1 vs. 12 
months; p=0.141).
Conclusions: Recurrence of HCC after liver transplantation is not 
uncommon. Aggressive surgical treatment may prolong survival in patients with 
IR only. Prognosis for patients with MR is dismal. Effective systemic therapy is 
urgently needed.
Keywords: Hepatocellular carcinoma; Recurrence; Liver resection; 
Transarterial chemoembolization; Liver transplantation; Targeted therapy
suitable for partial hepatectomy or local ablation were considered for 
LT. Before 2002, the radiological Milan criteria [2] (solitary tumor up 
to 5 cm in size, or a maximum of 3 tumor nodules with each no larger 
than 3 cm) were used for selection, but since 2002 the tumor number 
and size limits have been expanded to match the UCSF (University 
of California, San Francisco) criteria [8] (solitary tumor up to 6.5 cm 
in size, or a maximum of 3 tumor nodules with each no larger than 
4.5 cm and a maximum total diameter of 8 cm). Tumor evaluation 
was done using computed tomography of the abdomen and thorax, 
as well as radionucleotide bone scan at initial diagnosis. Recently, 
dual-tracer (carbon-11 acetate and fluoro-18 deoxyglucose) positron 
emission tomography has been used on selected patients to detect 
extrahepatic metastasis. For patients with prolonged waiting time, 
imaging studies were repeated every 3 to 6 months, and transarterial 
chemoembolization was given to control tumor growth for those 
with adequate hepatic reserve. Patients whose tumors progressed to 
beyond the acceptance criteria as seen on serial imaging were excluded 
from LT. Patients with major vascular invasion, extrahepatic disease 
or tumors beyond the UCSF criteria were not offered LT.
Introduction
Hepatocellular Carcinoma (HCC) is the leading cause of 
deaths among patients with hepatitis B, hepatitis C or related 
cirrhosis, and its incidence has increased over the past decade [1]. 
Liver Transplantation (LT) is the definitive treatment for it and the 
underlying liver cirrhosis. Unfortunately, HCC recurs in 10-60% 
of patients after LT [2-6]. The average time for recurrence ranges 
between 1 and 2 years, and some patients develop recurrence after 5 
years [6]. Treatment of recurrent HCC after LT remains a myth. The 
present study reviews the management of recurrent HCC after LT at 
our center.
Patients and Methods
Data of all adult patients who underwent LT at Queen Mary 
Hospital in the period from July 1994 to December 2007 were 
reviewed. The strategies used for the management and selection of 
patients with known HCC for LT have been described previously [7]. 
In brief, normally patients aged 65 years or below with disease not 
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For living-donor LTs, all living donors needed to have compatible 
ABO blood groups, as well as negative serology for hepatitis B surface 
antigen and hepatitis C antibody, and no evidence of any acute or 
chronic illness that would increase the operative risk. Computed 
tomography with volumetry was performed to determine the size of 
the donor liver, and the left or right liver lobe was selected to provide 
a graft larger than 40% of the recipient’s standard liver as estimated 
according to the University of Hong Kong formula [9].
Patients were followed up at our outpatient clinic weekly within 
the first 3 months of LT, and then every 1 to 3 months depending on 
their clinical status and results of liver function tests. Routine blood 
tests including liver and renal function tests were performed at every 
visit. Serum α-fetoprotein level check, chest X-ray and computed 
tomography (or magnetic resonance imaging for patients with 
impaired renal function) were performed every 3 to 6 months within 
5 years of LT, and thereafter every 6 to 12 months or when deemed 
indicated (e.g. if the serum α-fetoprotein level showed a rising trend).
Treatment for intrahepatic recurrence
The selection criteria for resection in liver grafts were the same 
as those for primary resection [10]. The resection techniques have 
been described in detail previously [10]. In brief, the criteria were 
(i) absence of extrahepatic disease, (ii) anatomically suitable disease, 
(iii) technically feasible disease, and (iv) absence of main portal 
vein or inferior vena cava tumor thrombus. All resections were 
conducted by experienced liver transplant surgeons. As a general 
guideline, sectionectomy or hemihepatectomy was performed for 
centrally located lesions, and wedge resection was performed for 
peripherally located lesions. Intraoperative ultrasonography was 
performed routinely for detecting undetected lesions in the liver. 
Liver parenchymal transection was performed with a Cavitron 
ultrasonic surgical aspirator. During liver transection, the central 
venous pressure was maintained below 5 mmHg by strict control of 
intravenous fluid administration so as to reduce venous bleeding from 
the liver. Hemostasis was achieved by suture, electrocautery or argon 
beam coagulation. Abdominal drain was not routinely deployed.
Patients with a solitary tumor ≤5 cm or ≤3 tumor nodules each 
≤ 3 cm who needed resection of large non-tumorous liver or had 
marginal liver function or difficult anatomical tumor locations (e.g. 
junction of major vasculatures) were subjected to radiofrequency 
ablation. 
Treatment for multiple or extrahepatic recurrence
Patients with multiple or extrahepatic recurrence were given 
best medical treatment and referred to the oncology department for 
consideration for possible systemic or targeted therapies.
Statistical analysis
The patients were divided into 3 groups for comparison: 
with intrahepatic recurrence (IR), with multiple (>3 intrahepatic 
recurrences) or extrahepatic recurrence (MR), and with no recurrence 
(NR). No patients had suspicious extrahepatic metastasis at the time 
of transplantation. Hospital mortality was defined as death occurring 
during the same hospital admission for the primary operation. 
Comparison of categorical variables was performed using Pearson’s 
chi-squared test. Nonparametric continuous variables were compared 
using independent-samples Kruskal-Wallis test and presented as 
medians and ranges. Parametric continuous variables were compared 
using Student’s t test and presented as means with standard deviation. 
Survival was analyzed by the Kaplan-Meier method, and comparison 
of variables was performed with the log-rank test. P values <0.05 were 
regarded as statistically significant and all p values were two-tailed. 
Significant factors (p<0.1) were put into a multiple logistic regression 
to determine independent factors associated with survival.
Results
Two hundred and fifty-two patients were included in the analysis. 
HCC recurrence occurred in 35 (13.9%) patients, 3 with IR and 32 
with MR. Patients in the IR and MR groups had a younger age (51 vs. 
51 vs. 56 years; p=0.007), a higher pretransplant serum α-fetoprotein 
level (27 vs. 97.5 vs. 18 ng/mL; p=0.005), more tumor nodules on 
histopathology (4 vs. 2 vs. 1; p=0.003) and a higher incidence of 
lymphovascular permeation (33% vs. 59% vs. 27%; p=0.001) than 
patients in the NR group (Table 1 and Table 2). More patients in the 
IR and MR groups had tumors beyond the UCSF criteria (67% vs. 56% 
vs. 17%) and tumors at stage IIIA or above (p<0.001) when compared 
with the NR group (Table 2). The preoperative and postoperative 
viral loads for infections of hepatitis B virus (HBV) and hepatitis C 
virus (HCV) are listed in Table 3. Entecavir was given to patients who 
had a high HBV DNA load, and interferon-based therapy was given 
to patients with a high HCV RNA load. On multivariate analysis, 
patient age, salvage LT and tumor status beyond the UCSF criteria are 
independent risk factors for HCC recurrence (Table 4). Table 5 shows 
the treatments for recurrence given to patients in the IR and MR 
groups. The overall 1-year, 3-year and 5-year patient survival rates 
were 100%, 66.7% and 0% respectively in the IR group, 93.8%, 43.5% 
and 23.9% respectively in the MR group, and 96.7%, 95% and 92.7% 
respectively in the NR group. Longer patient survival was found in 
the IR group when compared with the MR group (p<0.001) (Figure).
IR (n=3) MR (n=32) NR (n=217) P
Male : Female 3 : 0 29 : 3 179 : 38 0.378
Median age 
(years) (range) 51 (48 - 56) 51 (40 - 63) 56 (3-72) 0.007
Diagnosis 0.998
Cirrhosis 3 29 194
Chronic active 
hepatitis 0 1 4
Cirrhosis 
with acute 
deterioration
0 2 16
Biliary atresia 0 0 1
Primary biliary 
cirrhosis 0 0 2
Carrier of HBV 3 32 172 0.012
Carrier of HCV 0 0 29 0.071
Carrier of HBV 
and HCV 0 0 3 0.783
Median pre-LT 
α-fetoprotein 
(ng/mL) (range)
27 (21 - 1793) 97.5 (2 - 117850) 18 (1 - 38001) 0.005
Median pre-
recurrence 
α-fetoprotein 
(ng/mL) (range)
8 (3 - 10) 18 (2 - 307) -- 0.099
Salvage LT 0 17 34 0.000
Table 1: Comparison of demographic and clinical data of the 3 groups.
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Discussion
Around 8% of Hong Kong residents are HBV carriers, and most 
of the HCC cases in Hong Kong are caused by the virus. According to 
the Surveillance of Viral Hepatitis in Hong Kong – 2010 Update Report 
conducted in 2011 by the Department of Health of the Hong Kong 
government, about 10.4% of male adults and 7.7% of female adults 
were positive of hepatitis B surface antigen. On the other hand, places 
where HCV infection is epidemic such as Japan and the United States 
has seen a surge of liver cirrhosis and HCC related to the virus [1,11].
In 2009, the LT program in Hong Kong started to adopt the 
‘bonus points’ system for stage-2 HCC [12]. The system has increased 
the number of LTs for HCC considerably, which now account for 
one third of all LTs in Hong Kong. Concomitantly, the incidence of 
HCC recurrence after LT is on the rise. This desperate issue requires 
more attention than ever before. Treatments for HCC recurrence 
are highly variable. Therorectically, all treatments for HCC can be 
applied to treat its recurrences after LT, but the nature would be 
different. Treatments for HCC recurrences after LT are palliative in 
nature since they are ‘systemic’ recurrences. Nonetheless, aggressive 
treatment can be offered to patients who have IR only.
In the study, all the 3 patients in the IR group underwent resection 
of the liver graft and further recurrences were treated by transarterial 
chemoembolization or radiofrequency ablation. The overall survival 
of patients with IR was significantly longer than that of patients with 
MR (59 vs. 30.4 months; p<0.001) although the time of recurrence 
from transplant was comparable (23.1 vs. 12 months; p=0.141). One 
patient survived 3 year after treatments for IR.
At out center, patients with IR are subjected to surgical resection 
or radiofrequency ablation if they have fewer than 3 nodules, 
otherwise transarterial chemoembolization is administered. The 
aggressive approach has shown some evidence of prolonging survival. 
Nonetheless, recurrence pattern also plays an important role in 
IR (n=3) MR (n=32) NR (n=217) P
Explant tumor characteristics
Median tumor number (range) 4 (2 - multiple) 2 (1 - 20) 1 (1 - multiple) 0.003
Median largest tumor size (cm) (range) 3.2 (1.8 - 5.0) 3.2 (1.0 - 19.5) 3.7 (0.25 - 8.0) 0.094
Vascular permeation 1 19 58 0.001
Differentiation 0.065
Well 2 3 69
Moderate 0 23 110
Poor 1 2 12
Undifferentiated 0 0 2
Not mentioned 0 4 20
Milan – within : beyond 1 : 2 13 : 19 149 : 64 0.002
UCSF – within : beyond 1 : 2 14 : 18 176 : 37 0.000
AJCC staging system (2002, 6th edition) 0.000
I 0 7 87
II 2 16 116
IIIA 1 9 9
IIIB 0 0 1
Patient status – alive : dead 1 : 2 6 : 26 200 : 17 0.000
Graft status – functioning : lost 1 : 2 6 : 26 199 : 18 0.000
Overall patient survival 0.000
1-year 100.0% 93.8% 96.7%
3-year 66.7% 43.5% 95.0%
5-year 0% 23.9% 92.7%
Overall graft survival 0.000
1-year 100.0% 93.8% 95.7%
3-year 66.7% 43.5% 94.6%
5-year 0% 23.9% 92.4%
Median survival (months) 59.0 30.4 >222.8 0.000
Median follow-up (months) (range) 34.6 (29.7 - 59.0) 28.4 (8.5 - 139.8) 49.6 (0 - 222.8) 0.030
Median time from LT to recurrence (months) (range) 23.1 (21.1 - 44.8) 12 (3.3 - 71.2) -- 0.141
Table 2: Comparison of tumor characteristics and survival in the 3 groups.
AJCC: American Joint Committee on Cancer
J Hepat Res 1(3): id1014 (2014)  - Page - 04
Kenneth SH Chok Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
determining the prognosis. It seems that a larger number of tumor 
nodule and the presence of vascular permeation are associated with 
MR (Table 2). On multivariate analysis, tumor factors and salavge 
transplant were independent risk factors in survival. The finding 
echoed our previous report [13]. However, there could be selection 
bias for salvage transplant for poor-risk patients with failed primary 
treatment, so the outcome was also poor. Obviously, most patients 
are desperate after failure of their primary treatment and salvage 
transplant is bound to accept higher-risk patients in this regard, 
especially if a living donor is available after thorough discussion about 
the potential risks. Revised or modified patient selection criteria for 
salvage LT are needed in this context to better stratify the risks.
Patients with MR were treated with various therapies (Table 
4). Local excision included excision of solitary retroperitoneal 
nodule (n=1) and solitary peritoneal nodule (n=1). Two patients 
received excision of inferior vena cava tumor thrombus. The use 
of chemotherapy was not standardized and the most commonly 
used agents were doxorubicin, 5-fluorouracil and carboplatin. At 
our center, these various therapies are used to treat recurrences 
after treatment of HCC (LT or non-LT) and have been shown to be 
beneficial [6].
The drawbacks of this study are its retrospective nature, the 
small cohort size, and the heterogeneity of the patient population. 
IR (n=3) MR (n=32) NR (n=217)
HBV
Preop HBV DNA
Positive 2 15 81
Negative 1 17 90
No data 0 0 1
Postop first HBV DNA
Positive 0 4 13
Negative 3 28 157
No data 0 0 2
HCV
Preop HCV RNA
Positive / / 8
Negative / / 3
No data / / 18
Postop first HCV RNA
Positive / / 23
Negative / / 5
No data / / 1
HBV + HCV
Preop HBV DNA
Positive / / 2
Negative / / 1
Postop first HBV DNA
Positive / / 0
Negative / / 3
Preop HCV RNA
Positive / / 0
Negative / / 0
No data / / 3
Postop first HCV RNA
Positive / / 2
Negative / / 1
Table 3: Preoperative and postoperative viral loads for HBV and HCV infections.
P Odds Ratio
Age 0.000 0.891
HBV infection 0.997 1.550
Salvage LT 0.000 5.830
Pre-LT tumor status beyond UCSF criteria 0.000 6.728
Table 4: Multivariate analysis of independent risk factors associated with 
recurrence.
IR (n=3) MR (n=32) P
Liver resection 3† 0 0.000
Transarterial chemoembolization 2‡ 7 0.156
Systemic chemotherapy 0 13 0.279
Adrenalectomy 0 3 1.000
Lung resection 0 8 1.000
Alcohol injection 0 1 1.000
Interferon 0 3 1.000
Local excision 0 4 1.000
Intramedullary nailing 0 4 1.000
Radiotherapy 0 12 0.536
Percutaneous radiofrequency ablation 1‡ 2 0.242
Targeted therapy 1‡ 16 1.000
Open reduction and fixation 0 1 1.000
Tamoxifen 0 1 1.000
Thalidomide 0 3 1.000
Table 5: Treatments for recurrence.
† For recurrence for the first time
‡ For re-recurrences
MR (n=32) 
IR (n=3) 
NR (n=217) 
P<0.001 
Figure: Comparison of overall patient survival in the 3 groups.
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Moreover, there could be selection bias as this is a single-center study. 
However, our center has a strong experience in LT and hepatectomy, 
so the results may shed some light on the management of HCC 
recurrence after LT and may serve as a reference of note for other 
centers.
Conclusion
Aggressive treatment for intrahepatic HCC recurrence after LT 
may have some survival benefits for selected patients, but prognosis 
for patients with multiple or extrahepatic recurrence is dismal and 
effective systemic therapy is urgently needed. 
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